Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Qiagen N.V.
Qiagen sells the kits, chemicals, and lab machines that let scientists and hospitals purify genetic material and run molecular tests.
Qiagen is a life-sciences toolmaker. Its core job is sample preparation: turning a raw blood draw, swab, or tissue sample into clean, usable genetic material — DNA and RNA — that a lab can actually analyze. The company's kits and reagents are the picky, fiddly chemistry that separates the signal from the mess, and the machines and consumables that do it at scale are its bread and butter.
There are two big halves to the business. The first, often called Sample to Insight, sells the purification kits, instruments, and consumables that researchers and hospitals use every day; these are repeat purchases, like razor blades, which gives Qiagen a sticky base of recurring revenue. The second is molecular testing, where Qiagen sells diagnostic tests and platforms, including the QIAstat-Dx and NeuMoDx systems that hospitals use to detect infections and other conditions quickly. Qiagen also has a growing bioinformatics arm, selling software that helps labs make sense of the data once the sample is prepared. Who pays? Mostly pharmaceutical and biotech researchers, academic labs, and hospitals and diagnostic labs. They choose Qiagen because its kits are trusted, standardized, and used in regulated workflows — swapping suppliers means revalidating tests, which is a hassle nobody wants. Its main competitors in parts of the market are Thermo Fisher Scientific, Roche, and Danaher, though Qiagen's niche is the sample-prep step where it has long been a leader. The company is headquartered in the Netherlands but earns most of its money in the Americas and Asia, and it has been pushing growth in its diagnostic-testing franchise, especially after the pandemic boosted demand for molecular testing and then normalized it.
Qiagen generates solid free cash flow and spends it on dividends, share buybacks, and bolt-on acquisitions — it has a long habit of buying small tools and technologies to fold into its kits and platforms. The honest risks are real: it is exposed to research-spending cycles at universities and pharma companies, pricing pressure in diagnostics, and competition from bigger rivals with deeper pockets. It is a steady, unglamorous supplier that quietly sits underneath a huge amount of the world's medical and scientific work — the plumbing of the lab, in a sense.
Saved answer · last researched 12 Nov 2026